摘要目的 探讨"阴腹联合"腹腔镜阴道骶骨固定术治疗Ⅳ度盆腔器官脱垂的中期疗效.方法回顾性分析2010年1月1日至2017年7月30日因Ⅳ度盆腔器官脱垂在广州医科大学附属第一医院行"阴腹联合"腹腔镜阴道骶骨固定术患者65例的临床资料.通过比较术前、术后盆腔器官脱垂定量(POP-Q)分度法的各指示点位置评估客观疗效,以盆底不适调查表简表(PFDI-20)、盆底功能影响问卷简表(PFIQ-7)、盆底器官脱垂与尿失禁性功能问卷(PISQ-12)、患者整体印象改善评分(PGI-I)评估主观疗效.采用门诊和电话的方式随访.结果 65例患者均顺利完成手术,无术中并发症,术中出血量20~250 ml,术后留置尿管天数为(2.5±1.1)d,术后住院天数为(6.2±1.7)d.门诊随访53例,电话随访12例,随访时间为6.1～80.3个月,中位随访时间为24.5个月.术前、术后POP-Q指示点(Aa、Ba、C、TVL、Ap、Bp、gh)的位置分别比较,差异均有统计学意义(P均<0.01).阴道前壁、阴道顶端及阴道后壁脱垂Ⅳ度的客观治愈率分别为90%(47/52)、100%(23/23)和95%(20/21).PGI-I评分除1例患者为"有改善"外,其余64例(98%,64/65)均为"明显改善";65例患者术前、术后的PFDI-20、PFIQ-7、PISQ-12评分分别比较,差异均有统计学意义(P均<0.01),主观疗效显著.术后并发症:术后病率5% (3/65);网片暴露2例(4%,2/53),其中1例为阴道顶端网片暴露、1例为阴道前壁网片暴露.术后复发:6例患者(11%,6/53)术后脱垂复发,其中5例为阴道前壁脱垂复发,均为POP-QⅡ度,无脱垂相关症状,均未再次手术;1例为阴道后壁脱垂复发,诊断为阴道后壁脱垂Ⅲ度.无阴道顶端脱垂复发.再次手术率(包括暴露网片清除术2例及后盆腔重建术1例)为5%(3/65).结论"阴腹联合"腹腔镜阴道骶骨固定术对于Ⅳ度盆腔器官脱垂患者的主观治愈率高,阴道顶端脱垂的客观治愈率也高,网片暴露率低,再次手术率低,术后感染率低,是可选择的盆底重建术式之一;但对于阴道前壁脱垂Ⅳ度伴重度膀胱膨出的患者仍存在一定的复发风险.

abstractsObjective To evaluate the clinical effect after laparoscopic sacral colpopexy (LSC) of combined transabdominal-transvaginal approach on stage Ⅳpelvic organs prolapse (POP). Methods The clinical data of 65 patients undergoing LSC of combined transabdominal-transvaginal approach from January 1st, 2010 to July 30th, 2017 due to POP stage Ⅳ in First Affiliated Hospital of Guangzhou Medical University were retrospectively analyzed. Objective outcome was assessed by comparing preoperative and postoperative pelvic organ prolapse quantification (POP-Q) systems. Subjective effects were assessed by comparing pelvic floor distress inventory-short form 20 (PFDI-20), pelvic floor impact questionnaire short form (PFIQ-7), pelvic organ prolapse/urinary incontinence sexual questionnaire-12 (PISQ-12) and patient global impression of improvement (PGI-I). Results All 65 patients were successfully performed without any intraoperative complications. Fifty-three patients were followed in the clinic department and 12 were followed up by telephone. The follow-up duration was 6.1-80.3 months and the median follow-up duration was 24.5 months. The bleeding loss was 20-250 ml. Postoperative urethral catheter residence day was (2.5± 1.1) days, length of postoperative stay was (6.2±1.7) days. The postoperative POP-Q scores were compared with preoperative scores which had significantly improved except pb (all P<0.01). The objective cure rates of vaginal anterior wall, apical and posterior wall prolapse stageⅣwere 90% (47/52), 100% (23/23) and 95% (20/21).About PGI-I, except for 1 patient who chose"improvement", the other 64 patients (98%, 64/65) all chose"significant improvement". Furthermore, preoperative and postoperative PFDI-20, PFIQ-7, and PISQ-12 scores were all statistically significant (all P<0.01). Subjective efficacy was significant. Three cases (5%, 3/65) of postoperative fever occurred. Two cases (4%, 2/53) had mesh exposure. Six patients (11%, 6/53) had recurrence of postoperative prolapse. Five cases had recurrence of vaginal anterior wall prolapse and no reoperation was performed; 1 case was recurrence of posterior vaginal wall prolapse who diagnosed as vaginal posterior wall prolapse stage Ⅲ; no recurrence of apical prolapse. The rate of reoperation (including exposed-mesh removal and pelvic floor reconstruction surgery) was 5% (3/65). Conclusions The LSC of combined transabdominal-transvaginal approach has a high subjective efficacy rate. The objective cure rate in the case of apical prolapse stage Ⅳ is one hundred percent.The LSC of combined transabdominal-transvaginal approach has low mesh exposure, low postoperative infection and the reoperation rate, which is one of optional pelvic floor reconstruction surgery. However, there is still a risk of recurrence in patients with POP stageⅣwith severe bladder bulging.